SINGAPORE, Sept. 11, 2026 /PRNewswire/ — Dreame Technology is showcasing more than 100 products across 16 categories, demonstrating how Physical AI can move beyond the digital interface and become part of the physical world—helping products better perceive, understand, and respond to everyday life.

At the foundation of this ecosystem is Dreame’s Physical AI architecture, which integrates three core technology pillars: the Omni-Perception System, the Home Intelligence Model, and the Intelligent Actuation & Control System. Together, these enable products to perceive surroundings, interpret scenarios, make decisions, and translate them into physical actions—applying shared capabilities across diverse products and real-world use cases.

Smart Cleaning Flagships

Headlining the robot vacuum lineup is the X60 Ultra Extreme. Its Dual-Joint UltraExtend Arms allow the side brush to extend 12cm and the mop to reach 18cm into corners and under furniture. The ultra-slim 8.9cm design, liftable LDS module, and 42,000 Pa Vormax Suction ensure powerful cleaning in low-clearance spaces. AI-Enhanced OmniSight and 10cm ProLeap provide smooth navigation, while the PowerDock offers 100°C mop self-cleaning and up to 100 days of hands-free emptying.

Also unveiled is the Aqua20 Ultra Roller, Dreame’s first steam robot vacuum, using 180°C steam and 100°C hot water to melt grease and kill 99.99% of bacteria, with an 8cm extendable roller mop reaching deeper into recessed spaces.

For floor care, the H16 Pro TriForce combines 30,000 Pa suction, 200°C steam sterilization, 90°C hot water degreasing, and foam cleaning in one slim device, with a 9.85cm low profile and 180° lie-flat reach.

Personal Care Innovations

The Pocket Aura uses smart heat control and real-time distance sensors to reduce heat damage, low-heat drying and a foldable, travel-ready design. The Pocket Uni offers SmartVolt™ global voltage, 350 million negative ions, and a self-absorbing curling wand that styles with airflow. The AirStyle Pro HI is an 8-in-1 styling kit with a 130,000 RPM motor and Dreamehome app guidance, featuring A-Curl™ and a U-shaped straightening nozzle.

Air Purification Solutions

The FP10 Furcatch Air Purifier for pet owners captures 99.5% of pet hair and eliminates odors via six-stage purification with H14 HEPA and CataFresh™.

The TP20 delivers 500m³/h PCADR, refreshing a 20㎡ room in under 6 minutes, with a 3-in-1 filter lasting up to 5 years and 22dB quiet operation. The compact TP10 offers 280m³/h CADR for spaces up to 117㎡, consuming just 0.48kWh per 24 hours. The NP10 uses high-voltage electrostatic purification with a washable filter, delivering 400m³/h CADR at 28W.

Debuting is the RF10 Purifier Cool, a 2-in-1 purifier and fan with 120° wide-area airflow, millimeter-wave radar for person-tracking, and an 8-layer purification system with negative ions, consuming less than 1kWh per 24 hours.

From Intelligent Products to a Connected Smart Living Ecosystem

Dreame’s IFA 2026 presence reflects a shift toward an integrated ecosystem, applying common perception, decision-making, and execution capabilities across categories. With products in 190+ countries and 42 million households, Dreame continues to extend its Physical AI expertise into everyday life.

About Dreame Technology

Established in 2017, Dreame Technology is a trailblazer in smart home appliances that enhance lives through cutting-edge technology. The official distributor for Dreame Technology in Singapore is DM Dasher Pte Ltd. Stay updated by following us on Facebook, Instagram, and TikTok, or visit https://dreame.sg/.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/dreame-expands-beyond-smart-cleaning-with-full-smart-living-portfolio-at-ifa-2026-302875905.html

SOURCE Dreame Technology

A Chrono24 analysis of completed transactions from 2018 to Q2 2026 shows Rolex’s pandemic premium has fully unwound. The brand stays in front, but its lead has narrowed across every segment and younger buyers are spreading their money more widely.

• Under-30 buyers allocate the highest share of their watch spending to Rolex, about 34%. They have also pulled back the most: from roughly half the 2022 peak, a drop of around 30% in three years and the steepest of any age group.
• Rolex has given back share in every price segment since 2023, by 3 to 8 percentage points, as Cartier, Patek Philippe, Audemars Piguet and Vacheron Constantin gain ground.
• Demand is rotating from sports icons to the classic Datejust, now the single largest revenue-contributing collection at about 28%.
• Rolex accounts for 35% of watch transaction volume among North American buyers, its highest regional share, up from about 27% in 2018, while Asian demand has fallen from the low 30s to around 20%.

KARLSRUHE, Germany, Sept. 11, 2026 /PRNewswire/ — Rolex’s pandemic premium has fully unwound. Its marketplace share is back near the pre-2019 level after a 44% peak in early 2022, and prices are climbing again: the Rolex price index sits about 55% above 2019 and rose around 7% over the past year. The sharpest movement now comes from Rolex’s youngest buyers. These are among the results of a new analysis of Chrono24’s own marketplace data, covering 2018 to the second quarter of 2026. Rolex remains the largest brand on the Chrono24 marketplace at around 31% of dollar sales volume, ahead of Omega (about 11%) and Patek Philippe (about 6%). What has changed sits underneath that number.

After several years defined by pandemic-era price spikes and scarcity, the market has settled into a calmer phase. That makes this a useful moment to look at how buyers are behaving now that the boom is over, and the clearest answers sit in who is buying and what they choose.

Younger buyers are pulling back the hardest

Buyers under 30 still direct a larger share of their money to Rolex than any older group, about 34% against 27% for the over-60s. They are also retreating fastest. At the 2022 peak, the under-30s put roughly half of their watch spending into Rolex; that has since fallen by about 30% over three years, the steepest decline of any age group. Every age band has eased since the boom. The youngest buyers have moved furthest, toward dressier models and a wider set of challenger brands.

Rivals have recovered across every segment

Rolex still leads every price band above $5,000, and its grip is tightest in the $10,000 to $20,000 tier, where it holds about 61% of sales volume. Above $20,000 it holds close to 39%. That lead has thinned across the board since 2023, by 3 to 8 percentage points depending on the segment. The steepest slip came in its own stronghold: the $10,000 to $20,000 tier, where Rolex commanded more than 70% at the 2022 peak and now sits near 61%. Cartier gained the most in the $5,000 to $10,000 band, while Patek Philippe and Vacheron Constantin picked up ground above $20,000, where Audemars Piguet is also strong. Still, Rolex remains the reference point others are measured against.

Demand is rotating from the sports icons to the classic Datejust

For years the Submariner, GMT-Master II and Daytona defined what people wanted from Rolex. They still sell in volume and together make up close to 38% of revenue. The GMT-Master II is the recent standout, helped by scarcity: after Rolex discontinued the steel “Pepsi” at Watches and Wonders 2026, that reference traded about 24% higher than a year earlier, near $25,000, one of the biggest year-on-year gains among the best-sellers.

The deeper shift is toward dressier timepieces. With younger buyers driving demand away from speculative sports models and into versatile classic-dress styles, the Datejust has become Rolex’s single largest earner at around 28% of revenue. It is also where most collectors begin: the Datejust and Oyster Perpetual are the common entry points, and buyers tend to move on to the Daytona and vintage GMT-Master as they gain experience.

Women commit more to Rolex, and choose different models

Women direct roughly 38% of their watch spending to Rolex, compared with 30% for men. Both shares have normalized since the 2022 peak, with women down about 23% over three years and men about 17%. Their model mix differs, women concentrate on the Datejust and Oyster Perpetual, which come in the smaller case sizes many buyers prefer, while the Daytona, Submariner and GMT-Master II stay strongly favored by men.

Demand is shifting toward North America

The regional map is being redrawn too. North America is now Rolex’s strongest region: Rolex accounts for 35% of watch transaction volume among North American buyers, up from about 27% in 2018. Its share of spending among American buyers has risen steadily over the past eight years. Europe holds nearly 29%. Asia has moved the other way, from the low 30s to around 20%.

A market that has grown up

What emerges is a market that has widened around its leader. Three years after the peak, its buyers have moved on from chasing a few hyped references; they now spread their money with intent across a wider field. Rolex has not retreated; the field around it has caught up.

“The pandemic premium is unwound. The clearest signal is generational: younger buyers drove the boom, and they are the ones now moving to other brands and to classic watches like the Datejust. Rolex still sets the tone, but buyers spread their money across more brands than they did three years ago”, says Balazs Ferenczi, Head of Brand Engagement at Chrono24.

Learn More

• Read The Rolex Report 2026 and download the full research report
• Explore the world’s watch market on Chrono24, featuring new, pre-owned and vintage watches

Disclaimer

This report is an independent analysis by Chrono24 and is not affiliated with, endorsed by, or sponsored by Rolex SA.

About Chrono24

“Chrono24 – The World’s Watch Market” has been the world’s leading online marketplace for luxury watches since 2003. With more than 600,000 watches from over 3,000 dealers and 60,000 private sellers in more than 150 countries, the portal reaches more than nine million unique visitors per month. Chrono24 offers a comprehensive service portfolio with a large combined worldwide range of new, used, and vintage watches. This allows buyers and sellers to complete transactions in a trusted environment. Chrono24 employs over 350 people in offices in Germany (Karlsruhe and Berlin), Miami, Tokyo, Hong Kong, and other locations.

View original content:https://www.prnewswire.com/apac/news-releases/the-rolex-report-2026-the-same-leader-a-different-market-302875041.html

SOURCE Chrono24

HONG KONG, Sept. 11, 2026 /PRNewswire/ — September offers an opportunity to refresh everyday routines ahead of the busy year-end period. From nutrition and supplements to personal care and household essentials, wellness can take many forms in daily life. Global health and wellness retailer iHerb is highlighting six “Health Reset” essentials across adult nutrition, children’s supplements, personal care and household cleaning to support a range of everyday needs.

Marking its 30th anniversary this year, iHerb offers a broad selection of health, beauty and everyday essentials to customers around the world.

For consumers ready to turn their Health Reset intentions into action, now is an ideal time to explore iHerb’s selection of more than 50,000 products and discover the items that best suit their individual routines. As part of its 30th Anniversary Spotlight promotion, more than 600 participating brands are offering savings of up to 30% with promo code “IH30YRS” until 17 September at 1:00 a.m. New customers worldwide can also enjoy 25% off with code “NEW25”. In addition, up to 200 limited-time product deals will be added daily through 16 September, with selected items available at 40% off or more-giving shoppers even more opportunities to find new favourites for their personal reset.

Reset everyday habits and build a more consistent wellness routine

A refreshed routine can begin with simple, consistent nutritional habits. Alongside a balanced diet, supplements can help individuals meet their nutritional needs. Doctor’s Best Vitamin C, 500 mg provides 500 mg of vitamin C per serving in a vegetarian capsule, making it easy to incorporate into a daily supplement routine for consumers who want to support their everyday nutrition.

Another popular option is California Gold Nutrition Antarctic Krill Oil, which combines omega-3 phospholipids with naturally occurring astaxanthin. It comes in fish-gelatin softgels with natural strawberry and lemon flavour. From vitamin C to omega-3 supplementation, small and consistent daily habits can provide a practical foundation for a September wellness reset.

Refresh the family routine, from children’s nutrition to personal care

A Health Reset does not need to involve dramatic lifestyle changes. For families, it can start with small habits that are easy to maintain. Nature’s Way Alive! Kids Premium Gummy Multivitamin offers a convenient everyday supplement option for children aged two and above. It combines a range of vitamins and minerals in cherry, grape and orange-flavoured gummies that are easy to fit into a family routine.

 For those looking to refresh their hair-care routine, Force Factor Hair Growth Accelerator comes in mixed berry-flavoured soft chews designed for convenient daily use. It is formulated to support fuller-looking hair and can be incorporated into a consistent hair-care routine. Together, these options give families simple ways to identify the everyday habits that work best for them.

Reset the home, from laundry care to the bathroom

A reset can extend beyond personal routines to the home. Nellie’s Wow Stick Stain Remover offers a solid stain-treatment option for everyday marks on clothing and fabrics, while Seventh Generation Disinfecting Bathroom Cleaner is formulated for hard, non-porous surfaces and features a lemongrass citrus scent. Together, the two products offer practical options for refreshing everyday household routines.

iHerb expands its 30th anniversary offers with daily limited-time deals

To celebrate iHerb’s 30th anniversary, the Spotlight promotion will run from 3 September at 1:00 a.m. to 17 September at 1:00 a.m.. More than 600 participating brands will be featured, and shoppers can enjoy savings of up to 30% with promo code ‘IH30YRS’. New customers worldwide can also receive 25% off with promo code ‘NEW25’, making it easier to discover health and everyday essentials on iHerb for the first time.

Alongside the Spotlight promotion, iHerb will have up to 200 limited-time product deals each day through 16 September, with selected items available at 40% off or more across supplements, beauty, personal care and household categories. Products, discounts and promotion terms may change; the latest information on the official iHerb website will apply. Consumers can also follow the official iHerb WhatsApp account for the latest updates and get access to an exclusive 25% off promo code.

iHerb: A One-Stop Global Health and Wellness Platform

Headquartered in California, USA, iHerb is a global online retailer of health and wellness products. The platform provides Hong Kong consumers with access to authentic products through a safe and reliable cross-border shopping experience. Products are shipped directly from logistics centres in the United States and Asia, alongside the following delivery and shipping options:

• Fast delivery: Orders can arrive as fast as the next day.
• Free shipping: Enjoy free shipping on orders over HKD 150.
• Easy returns & refunds: For purchases made on the iHerb website or app, returns are accepted within 30 days from the day the order is received, while iHerb brand products enjoy an extended 90-day return period.

The featured products and anniversary offers are available through iHerb Hong Kong at https://hk.iherb.com/.

About iHerb (official website: https://hk.iherb.com/)

iHerb is a globally renowned US-based cross-border e-commerce platform specializing in high-quality health supplements, nutritional products, beauty and personal care, and daily essentials. Offering a curated selection of over 50,000 items and serving more than 180 countries and regions, iHerb is dedicated to helping global consumers access health and beauty options at reasonable prices. All products are shipped directly from multiple advanced logistics centers in the US and Asia, maintaining product freshness through rigorous cold-chain and temperature-controlled warehousing management . iHerb also continuously enhances its multi-language customer service and localized payment methods to ensure a safe, transparent, and convenient shopping experience for users worldwide.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/iherb-highlights-six-health–home-reset-essentials-302875051.html

SOURCE iHerb

• Samsung’s TV line-up has more Glare-Free options^[1] further catering to the 58% of Australians who love living on the sunniest continent on the planet but hate on-screen glare^[2].

• Samsung has expanded its ultra-large screen TV options to meet the demand of 60% of Australians who believe big screens offer more immersion^[3].

SYDNEY, Sept. 11, 2026 /PRNewswire/ — From sun-filled living rooms to bigger screens, art-inspired interiors and endless entertainment, Australians have their own way of watching TV.

As the Global No.1 TV brand for 20 years^[4], Samsung has developed a deep understanding of how Australians watch, live and entertain, designing TV experiences around the needs and preferences that make Australian homes and lifestyles unique.

Here are five key reasons Samsung TVs are made for Australians.

1.Made for Australian Homes: More certified Glare-free display technology that combats the Australian sunshine

Australians live in the sunniest continent on the planet^[6], but all that natural light can create one of the biggest frustrations when watching TV: on-screen glare. More than half of Australians (58 per cent) say glare is one of their biggest TV frustrations^[7].

Samsung’s certified Glare Free^[8] technology is designed to help Australians enjoy their favourite content with fewer distractions. By diffusing light, it helps reduce reflections on screen, making it easier to see what’s being watched in bright, sun-filled living rooms.

It’s a Samsung innovation designed around a distinctly Australian reality: our homes are beautifully bright, and our TVs need to work with that light, not against it.

2. Made for Australian Preferences: Australians want bigger screens to watch moments that matter with friends and family. 

Australians aren’t just going bigger, they’re going ultra-large. As TVs have grown in size and become more accessible, the big screen is increasingly becoming the centrepiece for how Australians come together, whether that’s watching sport, settling in for movie night or gaming with mates.

Size makes a real difference to the home entertainment experience. For Australians who love gathering around for big moments with friends and family, a larger screen can mean a more immersive experience while giving everyone in the room a great seat and viewing angle.

Samsung insights show that 60% of Australians believe the bigger the TV screen, the more immersed they feel in what they’re watching, while 68% agree bigger screens make content look more lifelike^[9].

Ultra-large screens are also becoming more accessible, with Samsung expanding its 98-inch-plus range from four options in 2025 to up to 10 by the end of 2026 across Micro RGB, The Frame Art TV, Neo QLED and Mini LED ranges. This means Australians have more choice across sizes, TV types and price points, providing an ultra-large screen option to more Australian living spaces^[10].

3. Made for Australian Lifestyles: Australians are bringing The Louvre, The Met and MoMA into their living rooms. 

For Australians who want their homes to reflect their personality, Samsung pioneered a range of Art TVs in The Frame and The Frame Pro TVs that transforms the TV into a piece of art when it’s not being watched. But not just any art. Samsung partnered with leading galleries and artists around the world to build The Art Store^[11] to bring Australians access to works from The Louvre, The Met, MoMA and Tate.

Fast forward almost a decade, Australians now consume more The Frame TVs per capita than any other country in the world^[12], exploring more than 5,000 artworks from over 800 artists via The Art Store^[13].

In response, Samsung has expanded Art Store beyond The Frame to two-thirds of its TV range^[14], allowing Samsung Micro RGB, OLED S95H, Neo QLED, QLED, Mini LED, and Movingstyle owners to welcome da Vinci’s Mona Lisa into their living room.

4. Made for Australian Entertainment: 200+ subscription free channels and cloud-gaming built-in and ready to go

From family viewing to solo streaming, Australians have more ways to entertain themselves than ever. Samsung brings many of those options together, with 200+ subscription free Samsung TV Plus channels^[15], top streaming apps, and Xbox Game Pass^[16] and Gaming Hub^[17] built in.

That means more entertainment is ready to go from the moment you switch your TV on, giving the whole family near endless ways to relax, watch and play without adding unnecessary complexity.

5. Made for Australian Viewing: Vision AI Companion making content discovery more personalised on the TV.

With near endless streaming choices at our fingertips, deciding what to watch can sometimes be the hardest part of the night.

Samsung’s Vision AI is designed to make the viewing experience more personal. It learns viewing habits, optimises picture and sound settings and recommends what to watch next, helping Australians spend less time searching and adjusting, and more time enjoying.

Further, Vision AI Companion (VAC) brings together Samsung’s broadest range of AI service platforms, including Bixby to make the TV experience more intelligent and personalised^[18]. Designed to work alongside users as an entertainment companion, VAC can help guide what to watch while watching Samsung TV+ channels, what to eat, and what to listen to, extending the role of the TV beyond viewing alone^[19].

Unlike AI designed for individual devices and users, Samsung Vision AI Companion is purpose-built for the communal TV screen^[20] using various LLMs to share visualised, intelligent responses adapted to Australian questions and requests^[21]. An upgraded version of Bixby sits at the core of Vision AI Companion which enables more natural dialogue, deeper contextual understanding, and personalised responses.

Samsung insights show that shared experiences with family around the TV is particularly important for Australians, with half of respondents claiming their TV brings their family closer together for quality time^[22]. In fact, 45% of respondents say the TV enables them to spend more time together, while 41% of respondents say the TV enables them to share passions and interests with their families^[23].

Vision AI Companion is available on Samsung’s entire 2026 TV range as well as being available on select 2025 models – Q7F or above^[24].

Supported by 7 years of Tizen upgrades, together, these innovations reflect what Samsung has spent 20 years learning as the world’s No.1 TV brand^[25]; great TV experiences aren’t one-size-fits-all.

From bright Australian homes and a preference for bigger screens, to design-led spaces and the way Australians discover and enjoy entertainment, Samsung continues to create TV experiences made for the way Australians live.

And after seven consecutive years as Australia’s Most Loved TV Brand, as voted by Australians in Finder Australia’s Customer Satisfaction Awards, that understanding continues to put Samsung at the heart of Australian living rooms.

###

About Samsung Electronics Co., Ltd.

Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, home appliances, network systems, and memory, system LSI, foundry and LED solutions, and delivering a seamless connected experience through its SmartThings ecosystem and open collaboration with partners. For the latest news, please visit the Samsung Newsroom at news.samsung.com.

View original content:https://www.prnewswire.com/apac/news-releases/made-for-australians-five-reasons-samsung-tvs-are-designed-for-australian-lifestyles-302875872.html

SOURCE Samsung Electronics Co., Ltd

Prestigious Life Sciences Platform and Awards Launch in Tokyo to Celebrate Breakthrough Innovation

TOKYO, Sept. 11, 2026 /PRNewswire/ — The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced that it will host the first Prix Galien Japan Forum, followed by an Awards Ceremony in the evening, on Thursday, February 25, 2027, at the Hotel New Otani, in Tokyo.

The inaugural event marks the first Prix Galien in Japan, recognizing the most transformative breakthroughs in pharmaceutical, biotechnology, medical technology, rare and orphan diseases, startup, and digital health solutions, while honoring the companies, researchers, and innovators whose work has altered the course of human health.

“My heartfelt congratulations on the launch of the Prix Galien in Japan,” said Nobel Laureate Prof. Tasuku Honjo. “This award recognizes that the cumulative efforts of long-term research generate value for society and carry forward the progress and integrity of science into the future.”

Awards will be presented across the following categories: “Best Pharmaceutical Product,” “Best Biotechnology Product,” “Best Product for Rare/Orphan Diseases,” “Best Medical Technology,” “Best Digital Health Solution,” and “Best Startup.” Winners are selected by the Prix Galien Japan Awards Committees, comprising leading biomedical scientists and industry executives from Japan and around the world.

“Through international collaboration, innovation in medicine advances hope and transforms lives worldwide,” commented Prof. Shinya Yamanaka, Nobel Laureate. “The launch of the Prix Galien Japan embodies this spirit.”

The Prix Galien Japan Awards Ceremony will precede a series of Prix Galien events in Asia, such as the Prix Galien India in New Delhi on March 18, 2027. The events celebrate the foremost leaders, innovators, and decision-makers in life sciences.

Event Details

Date: Thursday, February 25, 2027
Location: Hotel New Otani Tokyo

More details on the Prix Galien Japan Forum agenda to follow.

Sponsorship and attendance opportunities are available. For more information, please visit
www.galienfoundation.org or contact: [email protected]

About The Galien Foundation
The Galien Foundation fosters, recognizes, and rewards excellence in scientific innovation to improve human health. Its vision is to serve as a catalyst for the development of the next generation of treatments and technologies that will transform medical practice and save lives. Established in Paris in 1970 by Roland Mehl in honor of Galen, the father of medical science and modern pharmacology, the Prix Galien is widely regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

Today, the Prix Galien operates through 18 chapters spanning more than 75 countries across Africa, the Americas, Asia, and Europe. Expansion is currently underway in China, Singapore, and Australia.

In 2025, the Foundation launched the inaugural Prix Galien Bridges Forum and Awards Ceremony at the Nobel Forum in Stockholm, spanning Northern and Southern Europe, Israel, and the Middle East, and the first-ever Patient Summit for Prix Galien USA, reinforcing its commitment to science without borders.

The Nobel Prize and the Prix Galien share a common birthplace in Paris, where Alfred Nobel signed his last will and testament in 1895. However, while the Nobel Prize in Physiology or Medicine recognizes up to three individuals for specific discoveries, the Prix Galien honors the collaborative spirit and multidisciplinary progress that define modern biopharmaceutical innovation.

For more information, visit www.galienfoundation.org.

Follow the Foundation on social media: 
https://www.facebook.com/GalienFoundation/https://twitter.com/GalienFdn 
https://www.linkedin.com/company/the-galien-foundation/ 

Media Contact: 
Kara Bradley
Finn Partners 
[email protected]646-213-7243

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/the-galien-foundation-announces-inaugural-prix-galien-japan-forum–awards-ceremony-302873770.html

SOURCE The Galien Foundation

Total capital commitments of £680 million across Fund II and ancillary investment vehicles will support the acquisition and delivery of over 6,000 homes – as Starlight continues to strengthen its position among the UK’s largest BTR operators

TORONTO, Sept. 11, 2026 /PRNewswire/ — Starlight Investments (“Starlight”), a leading global real estate investment and asset management firm, has announced the successful closing of Starlight UK BTR Fund II (“Fund II”).

Fund II, together with capital raised through ancillary investment vehicles, reached £680 million in capital commitments and will support the acquisition and delivery of more than 6,000 build-to-rent (“BTR”) homes across the UK. Fund II is partially deployed and includes three significant rental communities under construction, including two in Manchester and one in Basildon.

Fund II’s successful closing represents a significant milestone in the continued expansion of Starlight’s UK platform and reflects investor confidence in the company’s BTR strategy, operational excellence, and disciplined execution. Fund II attracted strong participation from a diverse group of global institutional investors from across Europe, APAC, and Canada, including both existing limited partners and several new investors. Earlier this year, the Fund also received a major commitment from Homes England’s National Housing Bank, reinforcing the strategy’s alignment with country-wide efforts to increase the supply of much-needed rental housing.

“The successful close of Fund II reflects the strong institutional conviction behind Starlight’s UK residential strategy and the opportunity we continue to see in the market,” said Raj Mehta, President, Global Markets, Starlight Investments. “We are grateful for the continued support of our existing partners and pleased to welcome new investors to the platform. With the capital committed, we are well positioned to continue delivering homes in chronically undersupplied markets across the UK.”

“With Fund II now closed, our focus is on execution and the next phase of growth for our UK residential platform,” said Jonnie Milich, Head of UK Residential, Starlight Investments. “We have built a significant pipeline, an experienced local team and a growing portfolio of communities moving through construction, lease-up and operations. As we continue to advance our pipeline and bring new communities online, our portfolio will place us among the UK’s top four BTR operators by scale.”

Starlight’s broader UK platform is dedicated to the BTR sector, with a vision to deliver thousands of new homes across major regional cities and key London commuter belt markets experiencing pronounced rental housing undersupply. With 12 BTR communities spanning development through to active leasing and operations, the platform is focused on delivering professionally managed rental housing in markets supported by strong rental demand and economic fundamentals.

For more than three decades, Starlight has been a leading global real estate investment and asset management firm, delivering proven performance and responsible management across its real estate strategies. Starlight continues to broaden its global footprint, managing and investing on behalf of institutional partners across several continents.

About Starlight Investments

Starlight Investments is a leading global real estate investment and asset management firm headquartered in Toronto, Ontario, Canada. A privately held owner, developer and asset manager of over 70,000 multi-residential suites and over 7 million square feet of commercial property space with CAD $30 billion in AUM, Starlight offers a range of investment vehicles across various real estate strategies. Starlight’s guiding mission is to balance its tenure with visionary curiosity to create positive impact for investors and communities alike. At Starlight, we invest with impact.

Learn more at www.starlightinvest.com or connect with us on LinkedIn.

Contacts: Raj Mehta, President, Global Markets, +1-647-725-0498, [email protected]; Jonnie Milich, Head, UK Residential, +44-7930-373-945, [email protected]; Gwen McGuire, Director, Communications, [email protected]

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/starlight-investments-announces-successful-close-of-uk-btr-fund-ii-302874607.html

SOURCE Starlight Investments

Phase 3 study demonstrates benefits of the first influenza vaccine to combine three proven approaches to enhancing protection for older adults in a single vaccine.

MAIDENHEAD, United Kingdom, Sept. 11, 2026 /PRNewswire/ — CSL Seqirus, a business of CSL (ASX: CSL; USOTC: CSLLY), today announced publication of pivotal Phase 3 study results for its MF59^®-adjuvanted cell-based higher-dose quadrivalent influenza vaccine (aQIVc) in The Lancet Infectious Diseases, marking an important milestone in the evolution of influenza prevention for older adults.¹

The publication follows approval of the trivalent formulation of aQIVc by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom earlier this year for adults aged 50 years and older.² The vaccine, marketed as AUJEMFLU^®, has also been approved by the European Commission for adults aged 50 years and above.

The peer-reviewed publication reports findings from a large-scale study of the first influenza vaccine to combine three proven approaches to enhancing protection in older adults: MF59^® adjuvant, cell-based manufacturing, and a higher dose formulation compared to standard influenza vaccines.^1,3

Each of these approaches has been used separately in influenza vaccines for many years and is supported by extensive clinical and real-world evidence. This publication provides the first large-scale evaluation of their combination within a single vaccine.^1,2

Influenza remains a significant public health challenge, causing substantial illness, hospitalisations and deaths each year despite widespread vaccination programmes.⁴ 

Older adults are particularly vulnerable because the immune system becomes less responsive with age, reducing its ability to mount a strong protective response following vaccination.⁵ 

aQIVc combines three proven approaches to enhancing vaccine protection in older adults, with each playing a distinct and complementary role. Cell-based manufacturing helps preserve a closer match to circulating influenza strains, MF59® adjuvant strengthens, broadens and lengthens the immune response and a higher dose formulation further optimises that response.^2,6,7,8

The Phase 3 randomised immunogenicity and safety study enrolled 7,699 adults aged 50 years and older across eight countries and compared aQIVc with two enhanced influenza vaccines. The study met its primary objectives and demonstrated:¹

• Superiority versus the adjuvanted egg-based influenza vaccine comparator across all four influenza strains and age groups assessed.
• Non-inferiority versus a recombinant influenza vaccine for three out of four strains in the 50+ age group and four out of four strains in those aged 65+.
• Immune responses that persisted throughout the influenza season.
• A well-tolerated safety profile. Most reactions were mild or moderate and resolved within three days.¹  

The publication also reported exploratory findings of enhanced neuraminidase antibody responses versus comparators. The role of neuraminidase antibodies is an emerging area of influenza research that may contribute to reduced disease severity and broader protection beyond traditional measures of vaccine response.⁹

The study authors concluded that the findings support further evaluation of the vaccine and provide evidence for National Immunisation Technical Advisory Groups considering enhanced influenza vaccination strategies for older adults.¹

Regulatory submissions for the trivalent formulation of aQIVc have been made in multiple markets, with introductions expected to occur through a phased approach aligned to local regulatory, policy and access pathways.

Gregg Sylvester, Chief Medical Officer and Head of Research & Development, CSL Seqirus, said:
“Publication in The Lancet Infectious Diseases is a significant milestone for CSL Seqirus and reflects decades of investment in influenza vaccine innovation.”

“These findings provide important new evidence for healthcare professionals, policy makers and immunisation advisory groups considering future influenza vaccination strategies for older adults.”

Professor Colin Russell, Chair of the European Scientific Working Group on Influenza (ESWI) and Professor of Applied Evolutionary Biology at Amsterdam University Medical Center, said:
“Influenza vaccine innovation has historically progressed through incremental advances in technology and manufacturing. What makes this study noteworthy is that it shows the potential benefit of bringing multiple proven approaches together in a single vaccine.”

“Given the continued burden of influenza-related illness, hospitalisation and death among older adults despite widespread vaccination, these findings represent an important contribution to ongoing efforts to improve protection in this vulnerable population.”

About the Phase 3 Study
The randomised, observer-blind Phase 3 immunogenicity study enrolled 7,699 adults aged 50 years and older across Canada, Denmark, Estonia, Germany, Pakistan, the Philippines, the United Kingdom and the United States. Participants received either the MF59-adjuvanted cell-derived higher dose quadrivalent vaccine, an MF59-adjuvanted egg-based quadrivalent influenza vaccine or a recombinant quadrivalent influenza vaccine. The study evaluated immunogenicity, safety and manufacturing consistency.

About aQIVc
aQIVc is an MF59-adjuvanted, cell-based higher-dose quadrivalent influenza vaccine developed for adults aged 50 years and older.  The trivalent formulation has been licensed for use in people aged 50 and above in the UK and by the European Medicines Agency where it is marketed as AUJEMFLU.^®

The vaccine combines three proven approaches designed to enhance protection in older adults:

• MF59 adjuvant technology
• Cell-based manufacturing
• A higher dose formulation versus standard dose influenza vaccines
• Each dose contains 45 micrograms of haemagglutinin per influenza strain and 19.5 mg of MF59 adjuvant²

About CSL Seqirus
CSL Seqirus is part of CSL (ASX: CSL). As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness and response. With state-of-the-art production facilities in the US, the UK and Australia, CSL Seqirus utilises egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world. For more information about CSL Seqirus, visit www.CSL.com.

Intended Audience
This press release is issued by CSL Seqirus and is intended to provide information about our global business. Information relating to the approval status, product labels, recommendations and availability of CSL Seqirus products may vary from country to country. Please consult your local regulatory authority for information on approval status and local prescribing information.

Forward-Looking Statements
This press release may contain forward-looking statements, including statements regarding future results, performance, regulatory milestones, product availability or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these uncertainties, you should not place undue reliance on forward-looking statements.

For more information, please contact:
MEDIA CONTACT 
Alex Kiefer
[email protected]
Director International & Pandemic Communications, CSL Seqirus 

GL-aTIVc-26-0011

References

¹ Essink BJ, Vermeulen W, Andrade C, Mazur M, de Rooij R, Heijnen E, et al. Immunogenicity and safety of an MF59-adjuvanted cell-derived higher-dose quadrivalent influenza vaccine (aQIVc) in adults aged 50 years or older: a phase 3 randomised controlled trial. Lancet Infect Dis. In press 2026. Volume 26. September 2026.  THELANCETID-D-26-00167R3.
² Aujemflu suspension for injection in pre-filled syringe: summary of product characteristics [Internet]. Maidenhead: Seqirus UK Limited; 4 June 2026 (PL 47991/0020). Available from: https://www.medicines.org.uk/emc/product/102343/smpc cited 2026 Aug 2.
³ Ashraf M, Boivin W, Nguyen-Van-Tam JS, Nolan T, Stein AN, Russell CA. Development of an adjuvanted, higher-dose, cell-based influenza vaccine: combining advanced technologies to improve vaccine effectiveness. Expert Rev Vaccines. 2026;25(1):2667732. doi:10.1080/14760584.2026.2667732.
⁴ World Health Organization. Influenza (seasonal): fact sheet [Internet]. Geneva: WHO; 28 February 2025. Available from: https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)  cited 2026 Aug 28.
⁵ Cadar AN, Martin DE, Bartley JM. Targeting the hallmarks of aging to improve influenza vaccine responses in older adults. Immun Ageing. 2023;20:23. doi:10.1186/s12979-023-00348-6.
⁶ Essink BJ, Vermeulen W, Andrade C, de Rooij R, Isakov L, Casula D, et al. A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older. Vaccine. 2025;51:126791. doi:10.1016/j.vaccine.2025.126791.
⁷ de Looze F, Essink BJ, van Boxmeer J, Andrade C, de Rooij R, Casula D, et al. Immunogenicity and safety of higher-dose cell-based adjuvanted quadrivalent influenza vaccines: combined results of randomised, controlled dose-finding and dose-confirmation studies. Vaccine. 2026;79:128436. doi:10.1016/j.vaccine.2026.128436.
⁸ Ashraf M, Stein AN, Youhanna J, Rockman S, McMahon M, McGovern I, et al. The impact of egg adaptation and immune imprinting on influenza vaccine effectiveness. Vaccine. 2025;62:127393. doi:10.1016/j.vaccine.2025.127393.
⁹ Monto AS, Petrie JG, Cross RT, Johnson E, Liu M, Zhong W, et al. Antibody to influenza virus neuraminidase: an independent correlate of protection. J Infect Dis. 2015;212(8):1191-99. doi:10.1093/infdis/jiv195.

View original content:https://www.prnewswire.com/apac/news-releases/lancet-publication-marks-important-advance-in-influenza-prevention-for-older-adults-302875822.html

SOURCE CSL Seqirus

HONG KONG, Sept. 11, 2026 /PRNewswire/ — Hospitality has become the top real estate asset class for family office capital in Asia-Pacific, highlighting the sector’s growing appeal to private investors. IHIF Asia supports this increasingly important investor segment with dedicated content and networking opportunities for family offices and family office-owned property groups.

According to Knight Frank’s Wealth Report 2025, 44% of 150 family offices surveyed said they plan to increase their exposure to real estate over the next 18 months. “Family office capital represents an increasingly formidable investor base, with the ability to write cheques across a range of asset classes and geographies, both debt and equity,” says Cody Bradshaw, Group CEO, Hotels at L+R.

The session “Inside Family Office Capital: Decision Frameworks and Deal Strategy” will dive into how family offices evaluate deals, deploy capital and shape pricing across the region. It will be presented by Richard Zen, Founder & Managing Partner, Trivium Asset Management and moderated by Candice Wu, Co-Founder, Tigris Family Office.

Plus, a networking session on 17 Sep, the second day of the event, will unite attending family offices and family office-owned property leaders in a lounge setting. Attendees will have the chance to exchange perspectives on hospitality investment and connect with peers.

“There is a growing influence of family office capital in the Asia-Pacific hospitality industry,” said IB Saravanan, Vice President, Questex Asia. “IHIF Asia is creating an exclusive platform for these investors to connect, share insights and explore opportunities across the region.”

Hospitality Investor‘s latest report, The Family Office Report 2026 – APAC, showcases why and where family office capital is headed next. Access the exclusive report here.

The Industry Gathers in Hong Kong to Explore What’s Next for Asia Hospitality

IHIF Asia will take place 16-18 September 2026 at Regent, Hong Kong, bringing together more than 500 investors, owners, operators, developers and hospitality brands to explore the region’s next phase of growth.

Register to attend IHIF Asia here.

For media registration, contact Meryl Franzman at [email protected].

About Questex

Questex fuels exceptional business connections—where every buyer and seller interaction matters. Through live events enriched with data insights and active year-round digital communities, we deliver measurable results. It happens here.

Media Contact
Meryl Franzman
IHIF Asia
[email protected]

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/family-offices-are-becoming-one-of-the-most-powerful-forces-in-hospitality-investment-in-asia-pacific-questexs-ihif-asia-highlights-growing-influence-of-private-capital-302875579.html

SOURCE Questex Asia

HOUSTON, Sept. 11, 2026 /PRNewswire/ — Shell Energy North America (US), L.P. (SENA), a subsidiary of Shell plc (Shell), has signed two transactions as part of its ongoing management of its US power portfolio:

• The acquisition of 100% equity in Hunlock Creek Generating LLC (Hunlock), which owns 169 megawatts (MW) of natural gas-fired generation capacity in Pennsylvania.
• The sale of interests in RISEC Holdings, LLC (RISEC) to Constellation Energy Generation, LLC for $715 million. RISEC owns a 609-MW, two-unit combined cycle gas turbine power plant that serves the New England power market.

“These transactions reflect our dynamic approach to managing our trading portfolio,” said Andrew Smith, Shell’s President of Trading & Supply. “We selectively invest in assets that strengthen our market position and create value, while remaining ready to realize value when market conditions present attractive opportunities.”

The acquisition of Hunlock strengthens Shell’s position in the PJM power market

The acquisition secures supply and capacity offtake for SENA in the Mid-Atlantic power grid operated by PJM Interconnection, the largest wholesale electricity market and grid operator in the USA.

Hunlock and its subsidiary own 169 MW of natural gas-fired generation capacity in Pennsylvania. The asset further strengthens SENA’s position in the PJM market through access to flexible gas-fired generation and reinforces Shell’s continued focus on investing in assets that complement its trading capabilities.

The sale of RISEC enables Shell to realize significant value on an accelerated timeline

SENA’s earlier acquisition of RISEC ensured continued access to the plant’s capacity and associated trading opportunities in the market, enabling SENA to deliver substantial value as part of its asset-backed trading portfolio. With this transaction, SENA will bring forward the return it expected to generate from its longer-term ownership through a significant gain on the sale.

Both transactions are subject to regulatory approvals and are expected to close in the first quarter of 2027.

Notes to editors 

• SENA’s focus is on power markets where it can play to its strengths, including trading and optimization, backed by increased access to battery energy storage systems and flexible power plants.
• PJM Interconnection manages the movement of electricity across 13 US states and the District of Columbia, serving more than 65 million people.
• SENA has maintained an energy conversion agreement with RISEC for the plant’s full electricity output since 2019, which will terminate upon completion of the transaction.
• Hunlock’s portfolio includes a two-unit, 125-MW combined-cycle power plant and a 44-MW simple-cycle peaking plant. Hunlock is currently owned by Riverview Power Holdings LLC, an indirect subsidiary of Castleton Commodities International LLC.
• The Hunlock acquisition is projected to generate returns that exceed Shell’s investment requirements for its power business as outlined at Shell’s Capital Markets Day in 2025.
• SENA is a leading full-service energy company providing a comprehensive suite of solutions to commercial and industrial customers across wholesale and retail power, natural gas and environmental products markets. Headquartered in Houston, Texas, with regional hubs across North America, SENA has been active in energy markets for more than 25 years and owns gas-fired generation in some of the largest power markets in the United States.

Cautionary Note

The companies in which Shell plc directly and indirectly owns investments are separate legal entities. In this press release “Shell”, “Shell Group” and “Group” are sometimes used for convenience to reference Shell plc and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to Shell plc and its subsidiaries in general or to those who work for them. These terms are also used where no useful purpose is served by identifying the particular entity or entities. ”Subsidiaries”, “Shell subsidiaries” and “Shell companies” as used in this press release refer to entities over which Shell plc either directly or indirectly has control. The terms “joint venture”, “joint operations”, “joint arrangements”, and “associates” may also be used to refer to a commercial arrangement in which Shell has a direct or indirect ownership interest with one or more parties.  The term “Shell interest” is used for convenience to indicate the direct and/or indirect ownership interest held by Shell in an entity or unincorporated joint arrangement, after exclusion of all third-party interest.

Forward-Looking statements
This press release contains forward-looking statements (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995) concerning the financial condition, results of operations and businesses of Shell. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions, including (without limitation) those concerning Shell’s strategy and operating plans, macroeconomic conditions, future energy demand, supply and product mix, commodity prices, demand for Shell’s products, production results and reserve estimates, development, execution and management of projects, energy transition and climate change, management of safety and environmental risks, costs, cash capital expenditures, technology advancements, legislative, judicial, fiscal and regulatory developments, regional conflicts and trading conditions, and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements include, among other things, statements concerning the potential exposure of Shell to market risks and statements expressing management’s expectations, beliefs, estimates, forecasts, projections and assumptions. These forward-looking statements are identified by their use of terms and phrases such as “aim”; “ambition”; ”anticipate”; “aspire”, “aspiration”, ”believe”; “commit”; “commitment”; ”could”; “desire”; ”estimate”; ”expect”; ”goals”; ”intend”; ”may”; “milestones”; ”objectives”; ”outlook”; ”plan”; ”probably”; ”project”; ”risks”; “schedule”; ”seek”; ”should”; ”target”; “vision”; ”will”; “would” and similar terms and phrases. There are a number of factors that could affect the future operations of Shell and could cause those results to differ materially from those expressed in the forward-looking statements included in this press release, including (without limitation): (a) price fluctuations in crude oil and natural gas; (b) changes in demand for Shell’s products; (c) currency fluctuations; (d) drilling and production results; (e) reserves estimates; (f) loss of market share and industry competition; (g) environmental and physical risks, including climate change; (h) risks associated with the identification of suitable potential acquisition properties and targets, and successful negotiation and completion of such transactions; (i) the risk of doing business in developing countries and countries subject to international sanctions; (j) legislative, judicial, fiscal and regulatory developments including tariffs and regulatory measures addressing climate change; (k) economic and financial market conditions in various countries and regions; (l) political risks, including the risks of expropriation and renegotiation of the terms of contracts with governmental entities, delays or advancements in the approval of projects and delays in the reimbursement for shared costs; (m) risks associated with the impact of pandemics, regional conflicts, such as the Russia-Ukraine war and the conflict in the Middle East, and a significant cyber security, data privacy or IT incident; (n) the pace of the energy transition; and (o) changes in trading conditions. No assurance is provided that future dividend payments will match or exceed previous dividend payments. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Additional risk factors that may affect future results are contained in Shell plc’s Form 20-F for the year ended December 31, 2025 (available at www.shell.com/investors/news-and-filings/sec-filings.html and www.sec.gov). These risk factors also expressly qualify all forward-looking statements contained in this press release and should be considered by the reader.  Each forward-looking statement speaks only as of the date of this press release, September 10, 2026. Neither Shell plc nor any of its subsidiaries undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information. In light of these risks, results could differ materially from those stated, implied or inferred from the forward-looking statements contained in this press release.

Forward-Looking non-GAAP measures
This press release may contain certain forward-looking non-GAAP measures such as free cash flow and underlying operating expenses. We are unable to provide a reconciliation of these forward-looking non-GAAP measures to the most comparable GAAP financial measures because certain information needed to reconcile those non-GAAP measures to the most comparable GAAP financial measures is dependent on future events some of which are outside the control of Shell, such as oil and gas prices, interest rates and exchange rates. Moreover, estimating such GAAP measures with the required precision necessary to provide a meaningful reconciliation is extremely difficult and could not be accomplished without unreasonable effort. Non-GAAP measures in respect of future periods which cannot be reconciled to the most comparable GAAP financial measure are calculated in a manner which is consistent with the accounting policies applied in Shell plc’s consolidated financial statements.  These forward-looking non-GAAP measures are provided to assist readers in understanding management’s use and expectations of such measures and may not be appropriate for other purposes. 

The contents of websites referred to in this press release do not form part of this press release.

We may have used certain terms, such as resources, in this press release that the United States Securities and Exchange Commission (SEC) strictly prohibits us from including in our filings with the SEC.  Investors are urged to consider closely the disclosure in our Form 20-F, File No 1-32575, available on the SEC website www.sec.gov.

SOURCE Shell Energy North America